No Data
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
Several Insiders Invested In Cytosorbents Flagging Positive News
CytoSorbents Hops on Alliance With Converge
Express News | Cytosorbents and Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment With Cytosorb in India
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment With CytoSorb in India
H.C. Wainwright Maintains Cytosorbents(CTSO.US) With Hold Rating, Maintains Target Price $1
No Data
No Data